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SUMMARY
The shared exon 2 of the p14ARF-p16INK4a locus is frequently mutated in human cancers. However, in con-
trast to the exon 1b-encoded N-terminal half of ARF, the function of the exon 2-encoded C-terminal half of
ARF has been elusive. Here, we report that the mitochondrial protein p32/C1QBP binds the ARF C terminus.
We show that p32 is required for ARF to localize to mitochondria and induce apoptosis, and that ARF muta-
tions specifically disrupting p32 binding can impair both of these functions. Wild-type ARF, but not a p32-
binding-deficient ARF mutant, localizes to mitochondria, reduces mitochondrial membrane potential, and
sensitizes cells to p53-induced apoptosis. These findings provide a potential explanation for the frequent
human cancer mutations targeting the ARF C terminus.INTRODUCTION
The mammalian p14ARF-p16INK4a locus (p19Arf in the mouse,
ARF and p16 hereafter) is frequently mutated in human cancers
at an overall frequency of approximately 40% (Kamb et al., 1994;
Nobori et al., 1994; Ruas and Peters, 1998). This extraordinarily
high incidence of mutation is believed to result from the gene’s
unusual organization. The locus contains three exons, desig-
nated 1a, 2, and 3, that encode the CDK inhibitor p16. About
20 kb upstream from exon 1a, the locus contains an additional
exon, 1b, from which a second transcript is initiated, encoding
ARF. The ARF transcript skips exon 1a and joins the common
exon 2 in such a fashion that ARF and p16 exist in alternate read-
ing frames with respect to the shared exon 2 (Sherr, 2001).
Via distinct mechanisms, ARF and p16 activate the p53- and
pRb-mediated tumor suppression pathways, respectively. Inac-
tivation of both pathways by loss-of-function mutations repre-
sents a frequent, and perhaps obligatory, event in the develop-
ment of most human cancers (Vogelstein et al., 2000).
Targeted deletion in mice of the exon 2 shared by ARF and p16542 Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc.was shown to result in accelerated tumor development (Serrano
et al., 1996). Homozygous deletion of either ARF (exon 1b)
(Kamijo et al., 1997) or p16 (exon 1a) (Krimpenfort et al., 2001;
Sharpless et al., 2001) alone predisposes mice to tumor develop-
ment, indicating that both genes are bona fide tumor suppres-
sors. Enforced ARF expression causes cell-cycle arrest at both
the G1 and G2 phases in a p53-dependent fashion (Quelle
et al., 1995) by binding directly to and interfering with the p53
negative-regulator MDM2 (Kamijo et al., 1998; Pomerantz
et al., 1998; Stott et al., 1998; Zhang et al., 1998). In addition to
MDM2, many other ARF-interacting proteins have been identi-
fied, including E2Fs, DNA topoisomerase I, Pex19p, spinophi-
lin/neurabin II, a type 1 protein-phosphatase-binding protein,
B23/NPM, ARF-BP1, c-Myc, and CtBP (reviewed recently by
Sherr, 2006).
Endogenous ARF expression is known to be elevated by
oncogenic Myc, Ras, E2F1, E1A, and v-Abl—all of which activate
p53-dependent cell-cycle arrest—leading to the proposal that
ARF mediates a p53-dependent cell-cycle arrest checkpoint in
response to oncogenic signals (Sherr, 1998). In addition, ARFSIGNIFICANCE
Although ARF’s cell-cycle arrest function is well understood, little is known about ARF’s role in apoptosis, due largely to the
lack of specific molecules linking ARF to this process. The current view holds that the C terminus of ARF is dispensable for
tumor suppression because overexpression of the ARFN-terminal half alone is sufficient to activate p53. The study reported
here identifies mitochondrial p32 as a binding partner of ARF’s C terminus and a critical mediator of ARF’s apoptotic func-
tion in themitochondria. Importantly, the ARF-p32 interaction and ARF’s apoptotic function are simultaneously disrupted by
cancer-derived point mutations in the ARF C terminus. Our results provide mechanistic insight into ARF-induced, p53-de-
pendent apoptosis and demonstrate a potential tumor-suppressive function for the ARF C terminus.
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p53-mediated apoptosis that is induced by adenovirally ex-
pressed E1A and c-Myc (de Stanchina et al., 1998; Zindy et al.,
1998). Furthermore, apoptosis is increased in mouse embryo
fibroblast (MEF) cells engineered to overexpress c-Myc, E1A,
or E2F1; however, this effect is not seen in ARF null MEF cells,
and reintroducing ARF into the ARF null cells sensitizes them
to apoptosis induced by these oncogenes, confirming a critical
role in this process for ARF. ARF can also induce apoptosis in
cells lacking p53, although with slow kinetics, indicating that
ARF also has a p53-independent apoptotic function (Eymin
et al., 2003; Hemmati et al., 2002).
The shared exon 2 of the human p14ARF-p16INK4a locus suf-
fers frequent point mutations in cancer that are predicted to
affect the protein sequences of p16 and ARF either individually
or simultaneously, and most of these point mutations are clus-
tered at the 50 portion of exon 2, which is shared by p16 and
ARF. Of 661 cancer-derived alterations compiled for the entire
exon 2 (Greenblatt, 2006; Greenblatt et al., 2003; Ruas and Pe-
ters, 1998; Sharpless, 2005), 560 (85%), including 504 sporadic
and 56 germline mutations, are clustered in the 50 portion shared
by ARF and p16 (see diagram in Figure 4B). Among these, 118
(21%) are frame-shifting small deletions and insertions that trun-
cate the C-terminal sequences of both ARF and p16, 260 (46%)
are point mutations that simultaneously affect the sequence of
both proteins, and 39 (7%) are point mutations that affect the
protein sequence of ARF, but not p16. The presence of these
cancer-associated mutations in the ARF C terminus suggests
a potential tumor suppressor function for this region, yet a gener-
ally held view is that ARF is not functionally affected by these
C-terminal mutations, because ectopic expression of the exon
1b-encoded N-terminal domain of ARF is sufficient to fulfill the
known biological roles of the full-length ARF protein, such as as-
sociation with MDM2 and activation of p53 to cause cell-cycle
arrest. It has been shown that some exon 2 mutations could
affect the function of ARF’s nucleolar localization signal, which
is located at the C-terminal half of human ARF (Zhang and Xiong,
1999). Nevertheless, the perception remains that only p16, but
not ARF, is functionally affected by the exon 2 mutations. Why,
then, the 50 portion of exon 2 shared by p16 and ARF is preferen-
tially subjected to cancer-associated mutations, particularly
those that are ARF specific, remains unexplained.
In this study, we have identified a binding partner for the C ter-
minus of ARF: the mitochondria-anchored protein p32 (a.k.a.
C1QBP, gC1qR, HABP1). Importantly, the ARF-p32 interaction
is disrupted by human cancer-derived point mutations in exon
2 of ARF, including mutations that affect only ARF but not p16.
We show that p32 is a critical mediator for both ARF mitochon-
drial localization and ARF-induced, p53-dependent apoptosis.
These findings provide a previously unknown apoptotic function
of ARF in the mitochondria and a potential explanation for ARF-
specific exon 2 mutations in human cancer.
RESULTS
ARF Interacts with Mitochondrial Protein p32
To better understand the biological functions of ARF, we sought
to identify ARF-associated peptides by carrying out a large-scale
coimmunoprecipitation (co-IP) following adenovirus-mediatedoverexpression of human ARF in cells, utilizing an antibody spe-
cific for the human ARF protein. A number of polypeptides were
copurified with ARF protein from the Ad-ARF infected cells, but
not from Ad-GFP infected control cells (Figure 1A). One of the
peptides identified by mass spectrometric analysis was the
mitochondrial protein p32. p32 (a.k.a. C1QBP for globular head
component factor C1q binding protein, gC1qR for receptor for
C1q, and HABP1 for hyaluronan-binding protein 1) was originally
Figure 1. ARF Interacts with p32
(A) Identification of ARF binding proteins by mass spectrometry. Extracts from
U2OS cells infected with adenovirus expressing GFP or ARF were immunopre-
cipitated with an anti-ARF antibody, resolved by SDS-PAGE, and visualized by
silver staining. Peptide bands unique to samples infected with Ad-ARF were
subjected to mass spectrometry. ARF, p32, B23 (a known ARF-binding pro-
tein), and IgG heavy and light chains (IgG-H and IgG-L) are indicated.
(B) Direct interaction between p32 and ARF. Full-length p32 and ARF were in
vitro translated in the presence of 35S-methionine. Equal amounts of p32 pro-
tein were incubated with (+) or without () ARF followed by immunoprecipita-
tion with an anti-ARF antibody. The resulting ARF immunoprecipitates were
separated by SDS-PAGE and visualized by autoradiography.
(C) Coimmunoprecipitation (co-IP) of endogenous ARF with ectopically ex-
pressed p32. H1299 cells (p53-negative, ARF-positive) were transfected
with Myc-p32 plasmid for 2 days, and cell extracts were immunoprecipitated
with anti-Myc antibody. Western blotting was performed with anti-Myc and
anti-ARF antibodies. Loading control represents 10% of cell lysate used for
co-IP.
(D) Co-IP of endogenous p32 with ectopically expressed ARF. Extracts from
U2OS cells infected with Ad-ARF were immunoprecipitated with anti-ARF
antibody. Western blotting was performed with anti-ARF and anti-p32 anti-
bodies. Loading control represents approximately 10% of cell lysate used
for co-IP.
(E) Co-IP of ARF with p32 from Raji cells. Cell extracts from Raji (Burkitt’s lym-
phoma, expressing endogenous ARF and p32) cells were immunoprecipitated
with anti-ARF antibody and blotted with anti-p32 and anti-ARF antibodies.
HL60 (leukemia, ARF-negative) cells served as a negative control.
(F) Increased ARF-p32 interaction following actinomycin D treatment. H1299
cells were treated with (+) or without () 5 nM actinomycin D for 36 hr. Cell ex-
tracts were immunoprecipitated with anti-ARF antibody and blotted with anti-
p32 and anti-ARF antibodies. Extracts from U2OS (ARF-negative) cells served
as a negative control. Loading control represents approximately 10% of cell
lysate used for co-IP.Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc. 543
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cells (Krainer et al., 1991) and was subsequently shown to be
expressed as a pro-protein of 282 residues whose first 73 resi-
dues contain a mitochondrial targeting signal and are cleaved
during maturation (Ghebrehiwet et al., 1994). p32 has been
shown to be a receptor for globular head component factor
C1q (Ghebrehiwet et al., 1994) and to play a role in RNA splicing
(Petersen-Mahrt et al., 1999) and oxidative phosphorylation
(Muta et al., 1997). It is localized predominantly in the mito-
chondrial matrix (Dedio et al., 1998; Muta et al., 1997) and was
recently implicated in mediating cellular apoptotic response (Ka-
mal and Datta, 2006; Sunayama et al., 2004). We confirmed a di-
rect physical interaction between ARF and p32 by a coupled in
vitro transcription/translation (IVT) assay using 35S-labeled p32
and ARF proteins (Figure 1B). A direct and specific interaction
between ARF and p32 was further confirmed by a GST pull-
down assay (data not shown). The in vivo ARF-p32 interaction
was demonstrated by co-IP of endogenous ARF with ectopically
expressed Myc-p32 in H1299 cells (p53 negative, ARF positive)
(Figure 1C), and reciprocally of endogenous p32 with ectopically
expressed ARF in U2OS cells (ARF negative) (Figure 1D). Fur-
thermore, we were able to show the ARF-p32 association
in Raji cells, which express endogenous ARF and p32, under
unstressed physiological conditions (Figure 1E). Finally, we
found that the physiological ARF-p32 interaction was enhanced
by treating cells with a low dose (5 nM) of actinomycin D, which is
known to delocalize ARF from the nucleolus to the nucleoplasm
(Lindstrom et al., 2000), suggesting that the interaction takes
place preferentially outside of the nucleolus (Figure 1F). To-
gether, these data indicate that p32 interacts with ARF both
in vitro and in vivo under physiological conditions.
p32 Is Critical for a Subset of ARF to Localize
to Mitochondria
The findings that p32 is predominantly a mitochondrial protein
while ARF isusually in the nucleolus raise a questionabout the sub-
cellular compartment in which the two proteins might interact or
colocalize. To address this question, we fractionated cell lysates
into cytoplasmic (Cyto) and mitochondrial (Mito) fractions and
examined the existence and the relative abundance of ARF and
p32 in each of the fractions. We chose two human cancer cell lines
(H1299and HCC1937)and a MEF cell strain (p53null) for the study,
based on the feature that they all express a relatively high level of
ARF protein due to their p53-negative status. We tested several
fractionation protocols and found that a combination of a hypo-
tonic buffer, digitonin, and Triton X-100 (see Experimental Proce-
dures) yields the cleanest cytoplasmic and mitochondrial frac-
tions, which do not contain detectable contaminations from
each other or from nuclear proteins (Figure 2A). With this fraction-
ation scheme, we detected a subset of total ARF protein in the
mitochondrial fractions from each of the cells (Figure 2A). On the
other hand, p32 was found exclusively in the mitochondria, as pre-
viously reported (Dedio et al., 1998; Muta et al., 1997). These evi-
dences show that ARF and p32 colocalize in the mitochondria
and suggest that the ARF-p32 interaction might be important for
ARF’s mitochondrial localization.
To study the role of p32 in ARF’s localization to the mitochon-
dria, we knocked down p32 in H1299 and HCC1937 cells by
siRNA, fractionated the cell lysates, and examined the level of544 Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc.mitochondrial ARF by western blotting. In both H1299 and
HCC1937 cells, transfection of the p32 siRNA led to approxi-
mately 70%–80% reduction of endogenous p32. This amount
of p32 reduction did not affect the total level of ARF expression,
nor did it apparently affect the growth properties of the cells (data
not shown). Importantly however, we observed a significant
reduction of the level of ARF in the mitochondria, and the reduc-
tion was roughly in proportion with the level by which p32 was
reduced (Figure 2B). Similar results were also seen in U2OS cells
(p53 positive, ARF negative) with ectopically expressed ARF
Figure 2. p32 Is Critical for a Subset of ARF to Localize to Mito-
chondria
(A) Mitochondrial localization of endogenous ARF. p53-negative H1299 and
HCC1937 cells, and p53/ MEFs were either prepared as SDS lysates (Total)
or separated into cytoplasmic (Cyto) and mitochondrial (Mito) fractions. Equal
amounts of protein were loaded in each lane. The membrane was blotted with
antibodies to p14ARF, p19Arf, p32, mt-Hsp70 (mitochondrial heat shock pro-
tein 70, a mitochondrial protein marker), Histone H3 (a nuclear protein marker),
and Actin (a cytoplasmic protein marker).
(B) Downregulation of p32 by siRNA inhibits ARF mitochondrial localization.
H1299 and HCC1937 cells were transiently transfected with a scrambled
siRNA (si-Scr) or a p32 siRNA (si-p32) for 3 days. The cells were then isolated
for mitochondrial fractions and analyzed by western blotting with indicated
antibodies.
(C) Downregulation of p32 by siRNA inhibits localization of oncogenic Myc-in-
duced mouse p19Arf to mitochondria. Freshly prepared wild-type MEFs were
infected with retrovirus carrying either no insert (pBabe) or oncogenic c-Myc
(pBabe-Myc) and selected with puromycin for 3 days. The cells were then tran-
siently transfected with scrambled siRNA (si-Scr) or p32 siRNA (si-p32) for 3
days. Total cell lysates and mitochondrial fractions were prepared and ana-
lyzed by western blotting with indicated antibodies.
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Apoptosis
(A) p32 depletion causes resistance of cells to
ARF-induced apoptosis. U2OS cells were trans-
fected for 24 hr with indicated siRNA and then
infected for 2 days with adenovirus expressing
either GFP or ARF. Cells that survived ARF overex-
pression were counted, and the percentages of
surviving cells relative to GFP-expressing control
cells were plotted. Error bars represent the mean
± SD of four independent experiments.
(B) p32 depletion attenuates ARF-induced apo-
ptosis. U2OS cells were treated as described in
(A) and collected for flow cytometry analysis of
cell-cycle profiles. The percentages of cells in S
and sub-G1 phases are shown.
(C) p32 depletion causes resistance of cells to
ARF-induced PARP cleavage. U2OS cells were
transfected with siRNA and infected with adenovi-
ruses as described above. Cell extracts were ana-
lyzed by western blotting with antibodies to indi-
cated proteins.
(D) p32 depletion causes resistance of wild-type
MEFs to c-Myc-induced apoptosis. Freshly pre-
pared MEFs were infected with retrovirus carrying
either no insert (pBabe) or oncogenic c-Myc
(pBabe-Myc) and were selected with puromycin
for 3 days. The cells were then transfected with
siRNA for 2 days and subsequently cultured with (+) or without () serum for 24 hr. The percentages of cells surviving the treatment were quantified, and the
results were plotted. Error bars represent the mean ± SD of four independent experiments.
(E) A portion of the MEFs described in (D) was analyzed for p32 knockdown, p19Arf expression, and PARP cleavage by western blotting. Note that a second p32
siRNA oligos (si-p32-2) gives rise to identical results as the first p32 siRNA (si-p32).(Figure S1A available online) and in primary MEFs with onco-
gene-induced ARF (Figure 2C). Furthermore, coexpression of
ARF and p32 significantly increased the level of ARF protein in
the mitochondrial fraction without changing the total ARF level
(Figure S1B), indicating that a high level of p32 facilitates
ARF’s mitochondrial localization. Thus, these findings indicate
that p32 is critical for a subset of ARF protein to localize to the
mitochondria, and this can occur both in unstressed ARF-
expressing tumor cells and in oncogene-challenged normal
fibroblast cells.
p32 Is Critical for ARF-Induced Apoptosis
To elucidate the functional significance of mitochondrial ARF
and its interaction with p32, we wanted to determine whether
p32 plays any role in ARF-induced cell-cycle arrest and/or apo-
ptosis. We carried out our study first in U2OS cells because the
cells undergo both growth arrest and apoptosis upon ectopic
ARF overexpression (Hemmati et al., 2002; Kim et al., 2004; Yar-
brough et al., 2002). We first reduced p32 expression by trans-
fection of p32 siRNA before infecting the cells with adenovirus
expressing ARF. We then examined cell death by microscopic
observation. Adenovirus-mediated ARF overexpression yielded
extensive cell death in U2OS cells; after 2 days of infection,
only about 25% of cells remained attached to the control plate
transfected with scrambled siRNA (Figure 3A, open bar, and
Figure S2, panel 2). In contrast, in samples transfected with
p32 siRNA, more than 70% of cells survived ARF overexpression
and remained attached to the plate (Figure 3A, filled bar, and
Figure S2, panel 4). We next examined the cells by flow cytom-
etry analysis. Knocking down p32 resulted in a significant reduc-tion in ARF-induced apoptosis (measured by percentage of cells
in sub-G1 phase) but had virtually no effect on ARF-induced S
phase reduction (Figure 3B), indicating that p32 is important
only in mediating ARF-induced apoptosis, but not growth arrest.
Consistent with this notion, western blotting analysis indicated
that a reduction of p32 attenuated ARF-mediated PARP (poly
ADP ribose polymerase) cleavage—a characteristic of cells
undergoing irreversible apoptosis—but did not affect ARF’s in-
duction of p53 (Figure 3C).
To further analyze the apoptotic role of p32 under a more
physiological condition, we tested whether inhibition of p32
expression could affect Myc-induced ARF-dependent apoptosis
in primary MEFs. For this purpose, early passage (P1–P3) wild-
type MEFs were engineered to stably express either pBabe vec-
tor (control) or pBabe-Myc. Apoptosis was subsequently trig-
gered by culturing near-confluent cells in serum-free medium
for 24 hr, and the cells surviving the treatment (those that
remained attached to the plate) were counted. As shown in
Figure 3D, in samples transfected with scrambled siRNA (si-
Scr), a combination of Myc overexpression and withdrawing se-
rum led to cell death in a majority of the cell population, with only
approximately 30% of cells remaining attached to the plate
(Figure 3D, column 4, open bar). In contrast, in samples trans-
fected with p32 siRNA (si-p32), more than 70% of cells survived
the treatment (Figure 3D, column 4, filled bar), indicating that
Myc-induced cell death in the primary MEFs depends on p32.
To further demonstrate that the reduction in cell death was due
to inhibition of apoptosis, we analyzed PARP cleavage in the
MEFs by western blotting. pBabe-mediated Myc overexpression
resulted in activation of ARF in the cells (Figure 3E, ARF panel). ACancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc. 545
Cancer Cell
Requirement of p32 in ARF-Mediated ApoptosisFigure 4. Cancer-Derived ARF C-Terminal Mutations Impair ARF-p32 Binding
(A) Mapping of the p32 binding domain on human ARF. Extracts from U2OS cells transfected with plasmids encoding various ARF deletion mutants were immu-
noprecipitated with anti-Myc antibody and blotted with anti-Myc and anti-p32 antibodies. A diagram of human ARF is shown with the indicated p32-binding site
(82–101).
(B) Cancer-derived mutations in the p14ARF/p16INK4a gene locus are clustered at the 50 portion of exon 2. The reported single missense mutations that affect the
p16 sequence alone (gray bar) or both p16 and ARF (black bar) are shown in regard to the amino acid sequence of p16 (Greenblatt, 2006). Hotspot mutations at
Arg98 and Arg99 of human ARF, overlapping with His83 and Asp84 in p16, are indicated with asterisks.
(C) Amino acid sequence of the exon 2-encoded human ARF C terminus. Individual mutations analyzed in (D) are indicated with downward arrows.
(D) Cancer-derived ARF C-terminal Arg mutations impair p32 binding. U2OS cells were transiently transfected with indicated plasmids expressing various Myc-
tagged ARF proteins. Cell extracts were immunoprecipitated with anti-Myc antibody and blotted with the indicated antibodies.combination of Myc overexpression and withdrawing serum
resulted in PARP cleavage (Figure 3E, lanes 7), and this was rel-
egated by depletion of p32 (Figure 3E, lanes 8). To rule out a po-
tential off-target effect of the p32 siRNA, we used a second pair
of p32 siRNA oligomers (si-p32-2), which produced identical
results (Figure 3E, lanes 9 and 10). Together, these results indi-
cate that p32 is a critical mediator for ARF-induced apoptosis
but is perhaps irrelevant to ARF-induced cell-cycle arrest.
Human Cancer-Derived ARF C-Terminal
Mutations Impair p32 Binding
To better understand the nature of ARF-p32 binding, we identified
the protein sequence in ARF that mediates its interaction with p32.
We constructed a series of Myc-tagged ARF deletion mutants,
transiently expressed them in U2OS cells, and determined the
interaction of each mutant protein with endogenous p32 by an
IP-western assay. Notably, unlike other ARF-interacting proteins
such as MDM2 and B23 that interact with the exon 1b-encoded
N terminus of ARF, p32 interacted with ARF via a sequence be-
tween residues 82 and 101 (aa numbers corresponding to human
ARF) in the exon 2-encoded C-terminal half of the ARF protein
(Figure 4A). Intriguingly, human cancer-derived small mutations
are frequently observed in exon 2 of the ARF-INK4a gene locus,
and these mutations are clustered at the 50 portion of exon 2 that546 Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc.is shared by ARF and p16 (Figure 4B). Previous studies have
shown that p32 interacts with several viral and cellular proteins
at sequence domains rich in arginine (Arg) (Figure S3) (Beatch
et al., 2005; Hall et al., 2002; Luo et al., 1994; Nikolakaki et al.,
1996; Wang et al., 1997). The ARF protein is rich in Arg (24 Arg
among 132 residues in human ARF; 18%), especially within the
area mapped for p32 binding, where 8 out of the 20 residues
(40%) are Arg (Figure 4C). Cancer mutations affecting each of
the eight Arg residues within the p32 binding area have been re-
ported, and many of these mutations are ARF specific (i.e., not
affecting p16 due to alternative reading frames). To determine
whether any of these Arg mutations might affect the ARF-p32 inter-
action, we constructed ARF mutants according to reported Arg
mutations and tested them for p32 binding in transiently trans-
fected cells. Remarkably, each of the Arg mutations within the
p32-binding domain significantly affected the ARF-p32 interaction
(Figure 4D, lanes 3–10), whereas non-Arg mutations (P94L, P94S,
L104I) and an Arg mutation (R115G) outside of the p32-binding
domaindid not (Figure4D, lanes 11–14). Noneof the Arg mutations
disrupted the interaction of ARF with MDM2 or B23, suggesting
that the impairment of ARF-p32 binding by the Arg mutations is
p32 specific (Figure 4D, MDM2 and B23 panels). Hence, these
data show that the ARF-p32 interaction specifically can be im-
paired by cancer-derived mutations targeting the ARF C terminus.
Cancer Cell
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in Apoptotic Function
To study how the mutations disrupting p32 binding could affect
ARF function, we constructed two adenoviruses expressing ARF
mutants (RR98,99LS and R98Q, designated RR and R), accord-
ing to hotspot mutations found in human patients (Figure 4B,
shown with asterisks), and compared growth arrest and apopto-
sis in U2OS cells expressing the mutant ARF. Consistent with
findings from our earlier experiments (Figure 3) and others (Hem-
mati et al., 2002; Kim et al., 2004; Yarbrough et al., 2002), over-
expression of wild-type ARF caused both cell-cycle arrest
and apoptosis in U2OS cells: the cell population in S phase
(Figure 5A, open bar) was reduced from approximately 28% to
11%, while the population in sub-G1 increased from 1% to about
24% (Figure 5A, filled bar). Notably, however, although overex-
pression of each ARF mutant (RR and R) resulted in an equivalent
level of cell-cycle arrest as that caused by wild-type ARF expres-
sion, the mutant ARF caused only a moderate increase in apo-
ptosis (Figure 5A, filled bar), despite expression of the mutant
proteins at equivalent or higher levels compared to wild-type
ARF (see inset in Figure 5A). These data indicate that the ARF
C-terminal mutants are impaired selectively in their apoptotic
function. To further investigate ARF’s apoptotic function, we ex-
amined PARP cleavage in cells overexpressing the ARF mutants.
As determined by immunostaining of ARF, increasing amounts of
moi (multiplicity of infection) result in higher levels of ARF expres-
sion in each of the infected cells (data not shown). As shown in
Figure 5B, even though PARP cleavage could be seen in cells
infected with adenoviruses expressing each of the ARF proteins,
including the mutants, the extent of PARP cleavage was evi-
dently lesser in cells expressing the ARF mutants than in cells
expressing wild-type ARF (Figure 5B). In contrast, the induction
of p53 by ARF was unaffected by these Arg mutations (Figure 5B,
p53 panel). These results, together with the cell-cycle studies
shown in Figure 5A, suggest that ARF’s apoptotic function is se-
lectively affected by cancer-associated C-terminal Arg muta-
tions that disrupt its binding with p32.
To investigate whether p32 could augment ARF’s apoptotic
activity, we ectopically expressed p32 in U2OS cells along with
ARF or the ARF mutants and examined PARP cleavage by west-
ern blotting. ARF overexpression was adjusted to a low level so
that it would not by itself cause apoptosis in the cells. Coexpres-
sion of p32 with wild-type ARF increased PARP cleavage
(Figure 5C, lane 5); in contrast, the p32-binding-deficient ARF
mutant was unresponsive to p32 overexpression, and PARP
cleavage was not observed (Figure 5C, lane 6). Of note, overex-
pression of p32 did not stabilize endogenous p53, nor did it by
itself induce PARP cleavage (Figure 5C, lane 4). The ability of
p32 to augment ARF’s apoptotic function was further examined
by flow cytometry analysis. Consistently, p32 enhanced ARF-
induced apoptosis specifically, but not cell-cycle arrest, and
this synergistic effect was not observed when p32 was coex-
pressed with the p32-binding-deficient ARF mutant (Figure 5D).
Together, these data indicate that p32 augments ARF-induced
apoptosis specifically, and this function of p32 requires ARF-
p32 physical association.
Figure 5. p32-Binding-Deficient ARF Mu-
tants Are Attenuated in Apoptotic Function
(A) ARF C-terminal Arg mutations impair ARF’s
apoptotic function. U2OS cells were infected with
adenoviruses expressing either wild-type ARF
(ARF) or p32-binding-deficient ARF RR98,99LS
(RR) and ARF R98Q (R) mutants for 2 days. Cells
(both floating and attached) were collected for
flow cytometry analysis of cell-cycle distribution.
The fraction of cells in sub-G1 phase (filled bar)
and S phase (open bar) and the level of ARF pro-
tein expression (inset) are shown. Cell-cycle
profiles are also shown to the right. Error bars
represent the mean ± SD of three independent
experiments. p < 0.01 for pairwise comparisons
of cells in sub-G1 infected by wild-type ARF and
each of the mutants.
(B) ARF C-terminal Arg mutations impair ARF-me-
diated PARP cleavage, but not p53 induction.
U2OS cells treated as described in (A) were ana-
lyzed for PARP cleavage and p53 induction by
western blotting.
(C) p32 enhances ARF-induced PARP cleavage.
Cells were infected with adenoviruses expressing
the indicated proteins for 2 days and then har-
vested to be analyzed for PARP cleavage. Note
that p32-enhanced PARP cleavage was seen
only with wild-type ARF, but not the p32-binding-
deficient mutant ARF.
(D) p32 enhances ARF-induced apoptosis but not
ARF-induced cell-cycle arrest. U2OS cells were
infected with adenoviruses expressing the indi-
cated proteins for 2 days and harvested to deter-
mine the percentages of cells in sub-G1 and S
phase fractions by flow cytometry analysis.Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc. 547
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Mutant, Reduces Mitochondrial Membrane Potential
and Synergizes with p53 to Induce Apoptosis
To explore possible mechanisms by which the p32-binding-de-
ficient ARF mutant is impaired in its apoptotic function, we exam-
ined whether the ARF-p32 physical interaction is required in or-
der for ARF to localize to the mitochondria. We expressed both
the wild-type ARF and the p32-binding-deficient ARF (RR) mu-
tant in cells and examined the level of each ARF protein present
in the mitochondrial fraction by western blotting. Using the same
fractionation scheme and H1299 cells as shown in Figure 2, we
were able to obtain mitochondrial fractions containing no detect-
able nuclear or cytoplasmic proteins. We found that ectopically
expressed wild-type ARF could be readily detected in the mito-
chondria, while the RR mutant, although expressed at the same
level, was much less efficient in localizing to the mitochondria
(Figure 6A). A similar observation was also made in U2OS cells
(data not shown). This finding is consistent with the idea that
the ARF-p32 interaction is required to mobilize ARF to the
mitochondria.
It has been shown that a decrease in the mitochondrial inner
membrane potential (Dcm) is associated with early onset of apo-
ptosis (Green and Kroemer, 2004). To study the functional signif-
icance of ARF’s mitochondrial localization, we examined Dcm in
cells in the presence of both wild-type and RR mutant ARF. We
chose p53-negative H1299 and MDA468 cells for the experiment
in order to avoid ARF-induced, p53-dependent rapid apoptosis
and, more importantly, to allow us to examine ARF’s function
in mitochondria without the interference of p53 activity. The
Dcm was analyzed by incubating the cells with JC-1 dye (Cell
Technology, Inc., Mountain View, CA) followed by flow cytome-
try analysis. We adjusted ARF expression to a moderate level by
reducing the moi so that it would not cause apoptosis in the cells.
Under such conditions, we observed an evident decrease inDcm
in cells expressing wild-type ARF, but much less so in cells ex-
pressing the RR mutant ARF (Figure 6B). The same results
were also obtained in p53-negative Saos2 and HeLa cells
(data not shown). The decrease in Dcm as a consequence of
ARF expression was also observed in U2OS (p53-positive) cells
(Figure S4), suggesting that ARF’s ability to decrease Dcm is
a general phenomenon and possibly p53 independent. To as-
sess the physiological role of ARF in mitochondria, we examined
Dcm in primary MEFs under mitochondrial stress induced by
oligomycin—an inhibitor of mitochondrial ATP synthase (Chap-
pell and Greville, 1961) that is widely used to impose mitochon-
drial stress in cultured cells. We treated p53 null (p53/) and
ARF/p53 double null (p19Arf/;p53/) MEFs with 2 mg/ml of
oligomycin and examined their Dcm. In the presence of oligomy-
cin treatment, a reduction of Dcm was observed in both MEFs,
without signs of apoptosis. However, the reduction was much
more pronounced in p53/ MEFs than in p19Arf/;p53/
MEFs (Figure 6C). Together, these observations suggest that
the presence of ARF in the mitochondria sensitizes cells to mito-
chondrial stress and leads to loss ofDcm, but not necessarily ap-
optosis, which might also require the presence of p53.
Previous studies have shown that ARF-induced apoptosis is
mostly dependent on the function of p53. In the absence of
p53, ARF induces apoptosis only at a nonphysiological high level
of expression, and with slow kinetics. Consistent with this notion,548 Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc.we have observed that, in both ARF-overexpressing H1299 cells
and oligomycin-treated p53/ MEFs, even though the loss of
Dcm was evident, apoptosis did not occur. Because release of
cytochrome c from the mitochondrial intermembrane space
Figure 6. Wild-type ARF, but Not a p32-Binding-Deficient ARF
Mutant, Localizes to Mitochondria and Reduces Mitochondrial
Membrane Potential
(A) A p32-binding-deficient ARF mutant is impaired in mitochondrial localization.
p53-negative H1299 cells were infected with adenovirus expressing either wild-
type ARF (ARF) or a p32-binding-deficient ARF mutant (RR). Total SDS lysates
and mitochondrial fractions were prepared 2 days after infection and analyzed
by western blotting with antibodies to p32, ARF, mt-Hsp70,Histone H3, andActin.
(B) Wild-type ARF, but not a p32-binding-deficient ARF (RR) mutant, reduces
mitochondrial membrane potential (Dcm). p53-negative H1299 and MDA468 cells
were either uninfected (Mock) or infected with adenoviruses expressing wild-type
ARF (ARF) or a p32-binding-deficient ARF mutant (RR) for 2 days. Dcm was mea-
sured by incubating the cells with JC-1 dye followed by flow cytometry analysis. In
nonapoptotic cells (highDcm), JC-1 exists as a monomer in the cytosol (green, FL-
1) and also accumulates as aggregates in the mitochondria, which stains red (FL-
2). In apoptotic cells (low Dcm), JC-1 exists in monomeric form and stains the
cytosol green. Cells with preserved Dcm are high in both FL-1 and FL-2 (top right
of graph). Cells with loss ofDcm are high in FL-1 and low in FL-2 (bottom of graph).
Flow cytometry data plots are shown with percentage of total events indicated.
Data are representative of three independent experiments.
(C) Endogenous ARF sensitizes cells to mitochondrial stress, leading to reduction
of Dcm. Freshly prepared p19Arf
/;p53/ and p53/ MEFs were incubated
with acetone (as a control) or 2 mg/ml of oligomycin, an inhibitor of mitochondrial
ATP synthase widely used to generate mitochondrial stress in cultured cells. After
48 hr of oligomycin treatment, the cells were collected and analyzed for Dcm by
JC-1 dye.
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duce Cytochrome c Release
(A) ARF expression did not induce cytochrome c
release in H1299 cells. p53-negative H1299 and
p53-positive U2OS cells were infected with in-
creasing amounts of adenovirus expressing ARF
for 2 days. Total SDS lysates and cytoplasmic
fractions were prepared and analyzed by western
blotting with indicated antibodies.
(B) ARF synergizes with p53 to induce PARP
cleavage. Saos2 (p53-negative) cells were in-
fected with adenovirus expressing GFP, ARF, or
p53 as indicated. Cells were analyzed by western
blotting with antibodies against the indicated pro-
teins. Note that the level of ectopically expressed
ARF in the Saos2 cells is comparable to that of en-
dogenous ARF in the H1299 cells.
(C) A low level of p53 induces cytochrome c re-
lease in ARF-positive cells. p19Arf/;p53/ and
p53/ MEFs were infected with adenovirus ex-
pressing p53 at a low moi. Two days after infection,
total cell lysates and cytoplasmic fractions were
prepared and analyzed by western blotting.into the cytoplasm is considered a key initiative step in the apo-
ptotic process (Jiang and Wang, 2004), we therefore examined
whether or not this ARF-induced loss of Dcm leads to cyto-
chrome c release (Figure 7A). We infected p53-negative H1299
and p53-positive U2OS cells with increasing amounts of ARF ad-
enovirus. Two days after infection, cell lysates were collected,
soluble cytoplasmic (mitochondria-free) fractions were purified,
and the presence of cytochrome c in the cytoplasmic fractions
was analyzed by western blotting. Interestingly, even though
ARF was expressed to even higher levels (by increasing moi)
than those achieved in the Dcm assay, cytochrome c release
was not observed in ARF virus-infected H1299 (p53-negative)
cells. In contrast, the same level of ARF overexpression in
U2OS (p53-positive) cells triggered cytochrome c release, con-
sistent with the observed apoptosis in ARF-overexpressing
U2OS cells (Figures 3A–3C). These findings, together with the re-
sults from the Dcm assay, suggest that ARF, although ineffective
in causing apoptosis by itself, sensitizes cells to p53-induced
apoptosis.
To test this hypothesis directly, we ectopically expressed ARF
and p53 either individually or together in p53-negative Saos2
cells and examined PARP cleavage. We adjusted p53 expres-
sion to a low level so that it alone would cause only marginal
PARP cleavage in Saos2 cells, and we adjusted ARF expression
to a level equivalent to that of endogenous ARF in H1299 cells
(see Figure 7B, ARF panel in lanes 4–5). When expressed to-
gether, however, the same low levels of ARF and p53 led to ex-
tensive PARP cleavage (Figure 7B), indicating that ARF sensi-
tizes cells to p53-induced apoptosis. To study the role of ARF
in p53-induced apoptosis in a more physiological setting, we
transiently expressed increasing amounts of p53 in p53/ and
p19Arf/;p53/ MEFs and examined cytochrome c release
by western blotting. As shown in Figure 7C, in the p19Arf/;
p53/ MEFs, a small amount of cytochrome c release was ob-
served only with a high level of p53 expression (lane 4). However,
in the p53/ MEFs, which contain endogenous ARF, cyto-
chrome c release was observed with the lowest level of p53
expression; this effect was even more pronounced with a higherlevel of p53 (lanes 6–8). These results indicate that an endoge-
nous level of ARF is able to sensitize cells to p53-induced apo-
ptosis.
DISCUSSION
In the present study, we report identification of the mitochondrial
protein p32 as an ARF C-terminal domain-associated protein
whose association with ARF can be disrupted by human cancer-
derived point mutations in exon 2 of the p14ARF-p16INK4a gene
locus. We found that both p32 and ARF-p32 binding are required
for a subset of ARF protein to mobilize to the mitochondria (Figures
2 and 6). siRNA-mediated downregulation of p32 by up to 80% did
not affect cell growth and proliferation noticeably but significantly
inhibited apoptosis caused by either ectopic overexpression of
ARF in p53-positive tumor cells or induction of endogenous ARF
in wild-type MEFs (Figure 3), indicating that p32 is an essential me-
diator of oncogenic insult-induced, ARF-mediated apoptosis. The
identification of p32 as an essential mitochondrial binding partner
for ARF and a key modulator of ARF-induced, p53-dependent ap-
optosis extends the complex relationship between ARF and p53.
We adapted a mitochondrial fractionation protocol from
Ramsby and Makowski (1999) and were able to isolate clean
mitochondrial fractions (Figure 2A). With this method, we have
investigated the physiological function of ARF in the mitochon-
dria. We unexpectedly found that, at least in various p53-nega-
tive cancer cells and p53/ MEFs, a subset of full-length ARF
protein is in the mitochondria. Our study indicates that the local-
ization of ARF in the mitochondria reduces Dcm. This function of
ARF is likely independent of p53, because it was similarly ob-
served in both p53-positive and p53-negative cells. However,
ARF-mediated reduction of Dcm did not lead to apoptosis in
p53-negative cells, but did so only in the presence of p53 (Fig-
ure 7), indicating that a functional collaboration between ARF
and p53 is required for ARF-induced apoptosis to occur. Our
data are consistent with a model in which physiological ARF
and p53 must collaborate to induce efficient mitochondria-
mediated apoptosis (Figure 8). In this model, ARF, followingCancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc. 549
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via the exon 1b-encoded N terminus, thereby stabilizing and ac-
tivating p53 in the nucleus. Meanwhile, a subset of ARF interacts
with p32 via the exon 2-encoded C terminus and mobilizes to the
mitochondria, where it causes a decrease in Dcm. The activation
of p53 leads to further permeabilization of the ARF-weakened
mitochondrial membrane, resulting in release of mitochondrial
contents—such as cytochrome c—and apoptotic cell death.
Without p32 and/or mitochondria-localized ARF, p53-induced
cell-cycle arrest may still take place normally, but apoptosis
will be attenuated. This model is consistent with the findings
that downregulation of p32 by siRNA blocks ARF-induced apo-
ptosis specifically, but not cell-cycle arrest (Figure 3), and that
the p32-binding-deficient ARF mutants are impaired only in their
apoptotic, but not cell-cycle arrest, functions (Figure 5); in both
cases, ARF’s induction of p53 is unaffected. It has been reported
recently that a short isoform of ARF (smARF) translated from an
internal methionine localizes to the mitochondria through its in-
teraction with p32 (Reef et al., 2007), and when overexpressed,
smARF causes autophagic cell death (Reef et al., 2006).
However, we were unable to detect smARF in the mitochondrial
fractions using our fractionation protocol, although we did find
a small amount (1%–5% of total ARF) of smARF in the total
cell lysate in various human tumor cell lines (data not shown).
The reason for this discrepancy remains to be determined.
Studies of cultured cell lines have shown that cancer-
associated mutations inARF and p53 are general mutually exclu-
sive (Stott et al., 1998). One plausible explanation for this obser-
vation, according to the results presented in current study, could
be that ARF and p53 may depend on each other to induce apo-
ptosis. For example, a moderate level of p53 activation in the
absence of ARF (or mitochondrial ARF in particular) may be suf-
ficient to cause growth arrest, but not apoptosis. The same level
of p53, however, could be sufficient to cause apoptosis if ARF is
Figure 8. A Model for the Function of Mitochondrial ARF
Nuclear ARF stabilizes and activates p53 through its N-terminal interaction
with and inhibition of MDM2 (left). A subset of ARF also localizes to the mito-
chondria through its C-terminal interaction with mitochondrial p32 (right).
The mitochondria-localized ARF reduces Dcm and sensitizes cells to p53-in-
duced apoptosis.550 Cancer Cell 13, 542–553, June 2008 ª2008 Elsevier Inc.present in the mitochondria and therefore able to reduce Dcm.
Thus, the level of p53 activation in response to different environ-
mental cues, together with the status of ARF, could eventually
dictate the fate of the cells committing to either growth arrest
or apoptosis.
It is interesting to speculate that p32 might be mutated in the
course of cancer development, given its role in mediating ARF-
and p53-induced apoptosis. However, we have not found reports
indicating whether p32 is mutated in human cancer. Instead, it has
been shown that p32 is overexpressed in certain cancer cells (Ru-
binstein et al., 2004). This finding is not surprising because, in ad-
dition to its apoptotic role, as we found in this study, p32 also plays
important housekeeping roles in RNA splicing (Petersen-Mahrt
et al., 1999) and oxidative phosphorylation (Muta et al., 1997).
Cancer cells, which are more metabolically active, may require
more p32 to sustain fast growth and proliferation. Furthermore,
p32 is a downstream mediator of apoptosis for tumor suppressor
ARF, which itself is frequently mutated in cancer. Mutations in the
upstream tumor suppressor ARF could release the pressure for
mutations in the downstream p32.
Based mostly on in vitro overexpression systems, several pub-
lished studies imply that the ARF N-terminal region encoded by
exon 1b is sufficient for all known functions of the ARF protein,
leading to the notion that the exon 2-encoded ARF C terminus
does not possess any function (Kim et al., 2003; Lohrum et al.,
2000; Midgley et al., 2000; Quelle et al., 1997; Stott et al.,
1998; Weber et al., 2000; Zhang et al., 1998). Intriguingly, how-
ever, data from human cancer studies find that the majority of
small mutations in the p14ARF-p16INK4a gene locus cluster in
the 50 portion of exon 2 that is shared by p16 and ARF, including
those that are ARF specific, suggesting a tumor-suppressive role
for the ARF C terminus. Our findings that ARF-induced apoptosis
requires association of p32 with the exon 2-encoded C terminus,
and that both the ARF-p32 association and ARF’s apoptotic
function can be simultaneously disrupted by single point muta-
tions found in human cancers, has assigned a potential tumor-
suppressive function to the ARF C terminus. Whether or not
our in vitro data recapitulate the functional interaction of ARF
and p32 under a truly physiological environment can only be de-
termined definitively by introducing mutations into laboratory
animals. Nonetheless, this study has demonstrated a promising
role for p32 as a critical mediator of apoptosis, and these findings
provide a basis for further investigation into the role of p32 in
cancer development.
EXPERIMENTAL PROCEDURES
Cell Lines, Cell Culture, and Reagents
U2OS, H1299, HCC1937, MDA-MB-468, and Saos2 cells were obtained from
ATCC. Raji and HL60 cells were gifts from Dr. Beverly S. Mitchell (Stanford).
p19Arf/;p53/ MEFs were a gift from Dr. Norman Sharpless (UNC-Chapel
Hill). All cells were cultured in a 37C incubator with 5% CO2 in DMEM sup-
plied with 10% FBS. After each treatment, cell viability was determined micro-
scopically by trypan blue exclusion, and cell number was counted with a hem-
atocytometer.
Plasmids, Adenoviruses, and Flow Cytometry Analysis
Full-length p32 cDNA was purchased from Open Biosystems (GenBank
accession number BC000435), and both untagged and Myc-tagged full-length
p32 (aa 1–282) were cloned into a pcDNA3.1 vector (Invitrogen). All cloned
constructs were confirmed by direct DNA sequencing. Recombinant
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Requirement of p32 in ARF-Mediated Apoptosisadenoviruses carrying untagged p32, ARF, ARF mutants, p53, and GFP were
produced using the AdEasy XL Adenoviral Vector System (Stratagene) accord-
ing to the manufacturer’s protocol. The multiplicity of infection (moi) to achieve
more than 90% of cells infected by the adenovirus was determined by immu-
nofluorescence staining before carrying out experiments. Retroviruses ex-
pressing c-Myc proteins were produced as described previously (Itahana
et al., 2003). ARF point mutations were introduced by PCR-based site-directed
mutagenesis. For flow cytometry analysis, both floating and attached cells
were collected, fixed with 70% ethanol, stained with propidium iodide, and
analyzed at the UNC Lineberger Cancer Center Flow Cytometry Facility. The
software packages Summit (DakoCytomation) and ModFit LT (Verity) were
used for flow cytometry data acquisition, and all flow cytometry data are
representative of at least three independent experiments.
Protein Analysis
Rabbit polyclonal anti-p32 antibody was produced using a synthetic peptide
(CEERKIQKHKTLPKMSG) corresponding to amino acid residues 92–107 of
human p32. Antibodies for cytochrome c (7H8.2C12, BD PharMingen),
mtHSP70/GRP75 (H155, Santa Cruz), p19Arf (5-C3-1, Santa Cruz), Histone
H3 (9715, Cell signaling), PARP (C2-10, BD PharMingen), B23 (Fc-61991, Invi-
trogen/Zymed), Actin (MAB1501, Chemicon International), and MDM2 (4B11,
Calbiochem) were purchased commercially. Antibodies for human ARF (P02;
N terminus epitope), p53 (DO1), Tubulin (DM1A+DM1B), and Myc (9E10.3)
were purchased from Lab Vision/Neomarker. Rabbit polyclonal antibodies to
Myc, human ARF (C terminus epitope), and mouse ARF (C terminus epitope)
were gifts from Dr. Yue Xiong (UNC-Chapel Hill). The in vitro transcription/
translation (IVT) assay is described elsewhere (Enomoto et al., 2006). Cells
were lysed in 0.1% NP-40 buffer for immunoprecipitation and 0.5% NP-40
buffer for straight western blotting unless otherwise stated. For analysis of
PARP cleavage, both floating and attached cells were collected.
RNA Interference
The siRNA oligonucleotides targeting p32 mRNA, and the control scrambled
oligonucleotides (si-Scr), were synthesized either commercially by Dharmacon
(Lafayette, CO) or by using the Silencer siRNA Construction Kit (Ambion, TX).
The two targeting sequences for p32 are 50-GGUUGAAGAACAGGAGC
CUdTdT-30 (si-p32) and 50-UCACGGUCACUUUCAACATdTdT30 (si-p32-2)
(Sunayama et al., 2004). siRNA oligonucleotides (80 pmol) were transfected
using Oligofectamine (Invitrogen) or Lipofectamine (Invitrogen) in a 35 mm
dish according to the manufacturer’s protocol. All cultures were performed
without antibiotics during siRNA transfection. For adenovirus infection after
transfection, cells were transfected with siRNA oligonucleotides for 1–2
days, washed with medium, and infected with adenovirus for another 1–2
days.
Cytoplasmic and Mitochondrial Fractionation
Cytoplasmic extracts were prepared using a low concentration (0.15 mg/ml)
of digitonin solution adapted from Hemmati et al. (2006). Mitochondrial ex-
tracts were prepared using a low concentration (0.5%) of Triton X-100 (Fisher
Scientific) solution adapted from Ramsby and Makowski (1999) with slight
modifications. Briefly, both attached and floating cells were collected by cen-
trifugation and washed twice with PBS. One-fourth of the cells were lysed
with SDS lysis buffer (100 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol)
for direct SDS-PAGE analysis. The remaining cells were lysed in cold hypo-
tonic buffer (20 mM HEPES [pH 7.4], 10 mM KCl, 2 mM MgCl2, 1 mM
EDTA) supplemented with freshly made 1 mM PMSF and 0.15 mg/ml digitonin
(Sigma). After incubation on ice for 3 min, cellular debris, including nuclei and
mitochondria, were pelleted in a microcentrifuge (12,000 rpm) for 10 min at
4C. The supernatants were transferred to a fresh tube as the cytoplasmic
fraction. The cell pellets were further washed twice with cold hypotonic buffer
with 1 mM PMSF and then pelleted by centrifugation (12,000 rpm, 2 min). The
digitonin-insoluble pellets (containing mitochondria) were lysed with cold
0.5% Triton X-100/hypotonic buffer with 1 mM PMSF and incubated on ice
for 1 min. Subsequently, cellular debris including intact nuclei were pelleted
in a microcentrifuge (12,000 rpm) for 5 min at 4C, and the supernatants
were transferred to a fresh tube as the mitochondrial fraction. Both cytoplas-
mic and mitochondrial fractions were mixed with 53 SDS-PAGE loading
buffer before loading onto the gel.Measurement of Mitochondrial Membrane Potential
Both attached and floating cells were collected and washed twice with cultur-
ing medium. Equal concentrations of cells (13 106 cells/ml) were incubated for
15 min in culture medium containing 1X JC-1 dye (Cell Technology, Inc., Moun-
tain View, CA) at 37C in a 5% CO2 incubator according to the manufacturer’s
instructions. Cells were washed three times with culturing medium and ana-
lyzed by flow cytometry in the FL-1 and FL-2 channels. Mitochondrial perme-
ability transition was assessed with decreased red fluorescence (FL-2), which
indicates the presence of mitochondria with a lower membrane potential
(Dcm).
SUPPLEMENTAL DATA
The Supplemental Data include four supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/6/
542/DC1/.
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